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ABSTRACT
Alhayyani, Sultan. M.S. Microbiology and Immunology Graduate Program, Wright
State University, 2014. Expression of the Alpha, Beta, and Gamma Subunits of
the Interleukin-2 Receptor by Human Vascular Smooth Muscle Cells.

Interleukin 2 (IL-2) is a member of the cytokine family and contributes to
the proliferation, survival, and death of lymphocytes [1]. The interleukin-2
receptor (IL-2) is a tripartite receptor commonly expressed on the surfaces of
many lymphoid cells and is composed of three non-covalently associated
subunits, alpha (α) (CD25), beta (β) (CD122), and gamma (γ) (CD132) [2]. Our
laboratory has previously described IL-2 receptor β (IL-2Rβ) expression by
vasculature smooth muscle cells (VSMC) in mice and humans [3]. The current
work expands our previous observations by assessing the expression of the
alpha and gamma subunits of the IL-2R by VSMCs. Analysis of IL-2R expression
in human VSMCs revealed no detectable expression of the gamma subunit and
low expression of the alpha subunit. Treatment of VSMCs with IL-2 induced
VSMC proliferation with a concomitant increase in the expression of the gamma
subunit while having no detectable effect on expression of the alpha or beta
subunits. Treatment of VSMCs with LPS decreased expression of the beta
subunits and had little effect on alpha or gamma expression. Understanding the
mechanisms that regulate expression of the IL-2R by VSMCs and how binding of
this receptor by IL-2 mediates VSMC proliferation will provide a better
understanding of vascular biology and possible mechanisms underlying vascular
diseases such as atherosclerosis.
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Introduction
Smooth muscle is an involuntary non-striated muscle found within blood
vessel walls and many other many tissues. Bundles of myosin and actin
filaments within individual smooth muscle cells allow for contraction and
relaxation resulting in changing the shape and stiffness of hollow organs.
Contraction of vascular smooth muscle cells (VSMC) is responsible for the
redistribution of blood to areas where it is needed by altering local blood pressure
[4].
Interleukin 2 (IL-2) is a 15 kD glycoprotein and member of the cytokine
family. IL-2 regulates immune cell function by promoting the proliferation,
survival, and cell death of lymphocytes expressing the IL-2 receptor (IL-2R) [1].
The IL-2R is a tripartite receptor composed of three non-covalently associated
subunits, alpha (α)(CD25), beta (β) (CD122), and gamma (γ) (CD132). The β and
α subunits of the receptor bind to IL-2 while the β and γ subunits are responsible
for signal transduction [2].
Our laboratory has previously shown that SMCs within blood vessels of IL2 deficient mice exhibit a loss of smooth muscle cells compared to wild-type
controls [3]. Additional work from our lab described expression of the IL-2Rβ by
murine and human vascular smooth muscle cells [3]. The current work expands
our previous observations by assessing the expression of the α and γ subunits by
VSMCs. Analysis of IL-2R expression human VSMCs revealed no detectable
expression of the γ subunit and little expression of the α subunit. Exposure of
VSMCs to IL-2 increased VSMC proliferation with a concomitant increase in the
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expression of the γ subunit while having little effect on expression of the α and
the β subunits. In addition, exposure of VSMCs to bacterial lipopolysaccharide
(LPS), which has been reported to activate SMCs through interaction with the
Toll Like Receptor 4 (TLR4) [5], decreased the expression of β subunit while
having little effect on the expression of α and γ. These results suggest that IL-2
and factors that activate SMCs may have a direct effect on expression of the IL2R subunits by SMCs.
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Hypothesis: Human Vascular Smooth Muscle Cells (VSMC) express all
three subunits () of the IL-2R.

Aims of the current study:


Determine which subunits of the IL-2 receptor are expressed by
smooth muscle cells.



Determine how activation of smooth muscle cells impacts IL-2R
expression.



Assess how IL-2 affects smooth muscle cell function.
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Literature Background

Smooth Muscle cells:
Smooth muscle is an involuntary non-striated muscle found within many
tissues including blood vessel walls, lymphatic vessels, the gastrointestinal and
respiratory tracts, and iris of the eye. Bundles of myosin and actin filaments
within individual smooth muscle cells allow for contraction and relaxation
resulting in changing the shape and stiffness of hollow organs [4].
Vascular Smooth Muscle Cells (VSMCs) are a major component of blood
vessel walls and are responsible for altering local blood pressure thereby
providing increased blood flow to areas where it is needed. In addition, VSMCs
are important in the remodeling vessel tissue by proliferation, migration, and the
synthesis of large amounts of extracellular matrix (ECM), following pregnancy or
vascular injury [4]. VSMCs can perform both contractile and synthetic functions,
which are characterized by changes in morphology, proliferation, migration rates,
and the expression of different marker proteins. Alpha -smooth muscle actin (αSMA), smooth muscle-myosin heavy chain (SM-MHC), and cellular retinol
binding protein (CRBP) are some of the SMC marker proteins involved in SMC
contraction as structural components of the contractile apparatus or as a
contraction regulator. VSMCs in the vessel wall are diverse. This diversity is
reflected by the differential expression of contractile marker proteins, gap of
junction proteins, and adhesion molecules. This heterogeneous expression in
VSMCs is attributable to variations in gene expression and consequently SMC
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function. The diversity of VSMCs within a given length of vessel has been
proposed to make the vessel more responsive to various physiological or
pathological situations. In addition to their contractile and structural functions
within the vessel wall, VSMCs synthesize, secrete, and respond to small soluble
signaling molecules [6]. VSMCs synthesize IL-1, IL-6, IL-8, IL-11, TNF- α,
monocyte chemotactic peptides (MCPs), and macrophage migration inhibitory
factors (MMIFs)-1 α and -1 β [7, 8, 9, 10,11]. These cytokines and growth factors
stimulate SMC migration as an early event in vessel remodeling [12,13].

Vascular Smooth Muscle Cells Proliferation:
Under normal conditions VSMCs do not proliferate [14]. However, injuries
such as angioplasty, vascular stent implantation, or organ transplantation induce
VSMC proliferation [14,15,16]. Growth factors including platelet-derived growth
factor (PDGF), basic fibroblast growth factor, and insulin – like growth factor -1
promote VSMC proliferation [17,18]. The actions of these growth factors involve
nuclear factors including c-fos and c-myc that become active when the growth
factors bind to their respective cell surface tyrosine kinase receptors. These
nuclear factors work as transcriptional factors, leading to an increase in the
expression of various cell cycle regulatory proteins such as the cyclins and
cyclin-dependent kinases (CDK) [18,19]. To keep the proliferative response in
check, other factors inhibit VSMC proliferation. Such factors include CDK
inhibitors, which are divided into 2 different families based on their structure: the
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INK4 family (p14, p15, p16, p18, and p19) and the KIP/CIP family (p21, p27, and
p57) [20].

Vascular Smooth Muscle Cell Migration:
In the normal resting condition, VSMCs are non-migratory due, in part, to
being surrounded by a highly dense and adhesive matrix and the relative
absence of stimulatory factors [21]. Blood flow, sheer stress, cytokines, and
peptide growth factors are some of the factors that can affect VSMC migration
[21]. The initiation of migration begins with the activation of cell surface receptors
such as platelet-derived growth factor (PDGF) receptors which, in turn, activate
signal transduction pathways, trigger remodeling of cytoskeleton, decrease the
adhesive molecules in the matrix and activate motor proteins [22]. During
migration there is a decrease in the expression of cell-cell adhesive molecules
and focal contacts in the trailing edge of the cell and an increase adhesion of the
cell membrane to the matrix at the leading edge. Regulation of the actin
cytoskeleton occurs by several signaling pathways involving molecules such as
trimeric G proteins, small G proteins, lipid kinases, Ca2+-dependent kinases, and
Rho kinases [23].
There is also a link between migration and proliferation of VSMCs [24].
During VSMC proliferation, migration occurs only when the cell cycle is in the G1
phase but not in the later phases of the cell cycle. When the proliferation of
VSMC is inhibited by P21 and p27 proteins, inhibitors of VSMC proliferation,
VSMC migration is also inhibited. Overexpression of these inhibitor proteins
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leads to a reduction of human vein VSMC migration as well as proliferation [25,
26].

Interleukin-2:
Interleukin 2 (IL-2) is a 15 kD glycoprotein, a member of the cytokine
family, and is produced predominately by activated CD4+ and CD8+ T cells [1]. IL2 regulates immune cell function by promoting proliferation, survival, and cell
death of lymphocytes expressing the IL-2R [27]. IL-2 also acts as a downregulator of T cells leading to apoptosis. This feedback mechanism targets reactivated T cells in order to restrict the expansion of antigen-specific immune
responses [28, 29]. Other cells such as activated dendritic cells (DCs) and
natural killer (NK) cells produce IL-2, but the biological relevance of this
production is unclear [30, 31, 32]. IL-2 is produced following binding of the T cell
receptor (TCR) by costimulatory molecules such as CD28 on naïve T cells.
Transcriptional induction of the IL-2 gene is stringent. The promoter/enhancer
region for the IL-2 gene is approximately 500 base pairs upstream of the
transcription initiation site [33]. After TCR/costimulatory molecules bind, the TCR
signaling induces an increase in AP-1 and NF-kB levels, which in turn cause the
dephosphorylation of NFAT, leading to its translocation from the cytoplasm to
nucleus [34, 35]. These transcription factors bind to specific sites within the first
300 base pairs of the minimal promoter, leading to IL-2 gene transcription. T-box
transcription factor (T-bet) has been recently found to repress IL-2 production
through its interaction with Rel-A within the proximal IL-2 promoter [36]. IL-2
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inhibits its own production through a classical auto-regulatory feedback loop, this
loop depends on activation of signal transducer and activator of transcription-5
(STAT-5), and the IL-2-dependent induction of the transcriptional repressor Blymphocytes maturation protein-1 (Blimp-1) [37]. Thus, when naïve T cells
become activated, IL-2 is produced and binds to the IL-2 receptor (IL-2R), which,
in turn, leads to activation of STAT-5 and induction of Blimp-1, thence IL-2 gene
repression.

Interleukin-2 Receptor:
The IL-2R is a tripartite receptor composed of three non-covalently
associated subunits: alpha (α; CD25), beta (β; CD122), and the gamma (γ;
CD132). The γ subunit is common to the receptor complexes for at least six
different interleukin receptors: IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. The β and
the γ chains are related to the class I cytokine receptor superfamily, and exhibit
primarily folded β-sheet structures [2]. These three subunits are required for high
affinity IL-2 binding. IL-2 initially binds only the α subunit, which then promotes
association with the β and γ subunits. This IL-2/IL-2R quaternary complex
induces signaling pathways through the cytoplasmic β and γ tails [38, 39]. The
proteins Jak-3 via γ and Jak-1 via β phosphorylate key tyrosine residues, which
leads to binding between the adaptor Shc and either Stat-3 or Stat-5. Shc
activates two pathways: the mitogen-activated protein kinase (MAPK) and
phosphatidylinositol 3-kinase (PI3K). These two pathways are important for cell
survival and growth. After Stat is further phosphorylated, it dimerizes and
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translocates into the nucleus to regulate genes important in growth and function
of T cells [39]. IL-2/IL-2R binding on the cell surface is short-lived. After 10 to 20
minutes, the IL-2/IL-2R complex is internalized into the cytoplasm. IL-2, CD122,
and CD132 are degraded by lysosomes, whereas CD25 recycles to the cell
surface [40, 41, 42] [43]. CD132 is a shared subunit not only for IL-2R, but also
for IL-4, IL-7 IL-9, IL-15 and IL-21, and is expressed on all hematopoietic cells [2,
44]. Lymphoid progenitors, NK cells, NKT cells, memory phenotypic CD8 T cells,
and Foxp3+ Treg cells express CD122 subunit [45]. Most lymphoid cells, except
subsets of developing pre-T and pre-B cells, do not express CD25. Activated
effector cells, and natural CD4+ Foxp3+ Treg cells express CD25 [46].
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Materials & Methods
Human Vascular Smooth Muscle Cell Culture:
Human aortae, obtained from organ donors, were washed with PBS and the
adventitia was removed by gently scraping the outer surface with a scalpel blade.
A 2 cm2 piece was placed in a Petri dish and cut into1 mm2 pieces. The pieces
were placed lumen side down onto the surface of a TC-75 culture flask. The
flask was placed upright in an incubator at 37°C to allow the tissue to adhere to
the surface of the flask. After 4-6 hours, 10 ml of smooth muscle cell medium
was carefully poured into the flask so as not to dislodge the tissue. The aortic
pieces were cultured for 1-2 weeks before removal, and remaining cells were
passaged 4 times before use in assays.

In-cell Western:
VSMCs were cultured in black 96-well plates at an initial density of 5,000 cells
per ml. After incubation under conditions indicated in the figure legends, cells
were fixed in ice-cold methanol with 2% acetic acid v/v. After washing 3 times
with Tris-buffered saline/Tween-20 (TTBS), the cells were blocked for 2 hours
with Odyssey blocking buffer (Licor) containing 2% mouse serum. The antiCD25, anti-CD122, and anti-CD132 antibodies were added at 1g/well in TTBS
and incubated with the fixed, blocked cells in triplicate overnight at room
temperature. Isotype control antibodies were used at the same concentration as
the primary antibodies. The next day the cultures were washed 3X with TTBS,
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and probed for 1.5 h with streptavidin-680 (SA-680, Invitrogen) used at 1g/well
in TTBS. After a final wash, the plate was allowed to air dry in the dark and read
at 680 nm using a Synergy plate reader. (For additional details see appendix A)

IL-2 Binding Studies:
VSMC were cultured in 96-well plates at an initial density of 5,000 cells per well.
Cells were probed with one of two different IL-2 preparations previously
conjugated to a small molecular weight infra-red dye. Briefly, human IL-2 from a
bacterial source (unglycosylated) or mammalian cell line (glycosylated) was
labeled with an infrared dye (680LT, LI-COR Biosciences, Lincoln, NE) per the
manufacturer’s instructions. The activated infra-red dye was added to the IL-2 at
a molar ratio of 1:1. Following a 2 hour incubation at 20°C, unconjugated dye
was removed from the preparation using a Zebra Spin de-salting column.
Cells were probed with one of the two fluor-conjugated monomeric IL-2
preparations at the concentrations indicated in the figure legend for 20 mins at
4°C. To determine if antibodies against the subunit of the IL-2R would block
binding of the fluor-IL2, some cells were pre-incubated with 40ug/ml of antiCD122 for 30 minutes. Cells were then fixed with ice-cold methanol with 5%
acetic acid for 15 minutes at 4°C. The fixed cultures were washed 2 times with
PBS and read at 680 nm using a Synergy plate reader. (For additional details
see appendix B).
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SMC Proliferation Assay:
VSMCs were cultured in clear 96-well plates at an initial density of 5,000
cells per ml. Some cells were treated with IL-2 as indicated in the figure legend,
and incubated for 2, 4, or 6 days. Twenty µl of CellTiter 96 Aqueous One
solution reagent (Promega) was added to each well of the 96-well plate
containing the samples in 100µl of culture medium, incubated at 37°C for 1-4
hours, then read at 490nm using a Synergy plate reader. The CellTiter 96
Aqueous One Solution reagent contains 3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)- 2-(4-sulfophenyl)-2H-tetrazolium, which is reduced by
cells into a colored formazan product that is soluble in tissue culture medium.
This conversion occurs by NADPH or NADH produced by dehydrogenase
enzymes only in cells that are metabolically active. (For additional details see
appendix C)
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Results
Human Vascular Smooth Muscle Cell can express the Alpha, Beta, and
Gamma Subunits of the IL-2 Receptor.
To determine if human vascular smooth muscle cells (HVSMC) express
the Alpha, Beta, or Gamma subunits of IL-2R, we examined their expression
using an In-Cell Western analysis, in which cell surface expression of receptors
is assayed in fixed, cultured cells using fluorescently-labeled antibodies. As
shown in Figure 1, HVSMCs express Beta subunit, and to a lesser degree the
Alpha subunits. Little to no expression of the Gamma subunit was detected.

Dye-labeled glycosylated IL-2 binds vascular smooth muscle cells.
In light of the above results, we next asked whether IL-2 binds the IL-2R
expressed by HVSMCs. Cultured cells were incubated with glycosylated human
IL-2 labeled with a fluorescent dye (680LT, LI-COR Biosciences, Lincoln, NE).
The presence of carbohydrates mimics the in vivo situation wherein HVSMC’s
would be exposed to a glycosylated IL-2. To confirm that retention of the fluor-IL2 was mediated by the IL-2R, some cells were pre-incubated with an anti-CD-122
antibody. As seen in figure 2, fluor-monomer IL-2 bound to HVSMCs. Preincubation with anti-CD-122 decreased the binding of fluor-IL-2 three fold.

Dye labeled, non-glycosylated IL-2 binds vascular smooth muscle cells.
To assess the involvement of carbohydrates on IL-2 in mediating binding
to the IL-2R expressed by HVSMCs, binding of glycosylated fluor-IL-2 (above)
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was compared to binding of a non- glycosylated form of recombinant IL-2. Using
the same procedure as detailed above, HVSMC’s were found to bind nonglycosylated fluor-IL-2, and this binding was also inhibited by an anti-CD122
antibody. An approximately 2 fold decrease in the binding of non-glycosylated
fluor-IL-2 was detected in wells pre-incubated with Anti-CD122 antibody
compared to wells probed with dye labeled non-glycosylated IL-2 alone (Figure
3).

IL-2Rβ expression decreases in vascular smooth muscle cells after
exposure to lipopolysaccharide (LPS).
Having confirmed that HVSMCs express the Beta and Alpha subunits of
the IL-2R, we asked whether treatment of HVSMCs with LPS influenced IL-2R
subunit expression. To do so, VSMC were cultured with LPS for 48 hours, and
IL-2R expression was assessed. No appreciable change in the expression of the
Alpha or Gamma subunits was observed in response to exposure to LPS (data
not shown). However, Beta expression was observed to decrease (Figure 4).

Exposure of Vascular Smooth Muscle Cells to IL-2 increases expression of
the IL-2R gamma subunit (γ).
Based on the above results, we asked how IL-2 affects IL-2R subunit expression.
Cultured VSMCs were cultured with IL-2 for 24 hours and IL-2R subunit
expression was assessed. Interestingly, Gamma subunit expression increased in
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cells exposed to IL-2 compared to media only (Figure 5). No appreciable change
occurred in Alpha and Beta expression (data not shown).

Exposure of Vascular Smooth Muscle Cells to IL-2 increases SMC
Proliferation.
To determine if IL-2 affects VSMC proliferation, HVSMC’s were treated with
monomeric IL-2 and the proliferative response was assessed. Treatment of
HVSMCs with IL-2 resulted in an approximately 25 fold-increase in the number of
viable cells compared to wells receiving no IL-2.
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Discussion
Interleukin 2 is a 15-kD cytokine produced mainly by T cells. It plays a
critical role in regulating T cell proliferation, survival and death [1]. IL-2 binds with
high affinity to a tripartite receptor composed of alpha (CD25) (α), beta (CD122)
(β), and gamma (CD132) (γ) subunits that are expressed mainly on the surfaces
of lymphoid progenitors, NK cells, NKT cells, memory T cells, and T-reg cells
[45]. However, more recent studies from our lab and others have described
expression of the IL-2R on non-lymphoid cells including vascular smooth muscle
cells [47, 3].
Our laboratory recently described expression of the β subunit of the IL-2R
by murine and human VSMC’s [3]. Our current work reveals that VSMCs express
both the β and α subunits, and can be induced to increase expression of the of γ
subunit. To examine if the glycosylation state of IL-2 affects binding to the IL-2R
expressed on VSMC’s, we compared the binding of a glycosylated form of IL-2
with a non-glycosylated form. No appreciable difference was detected between
the glycosylated and non-glycosylated forms, suggesting that the IL-2R
expressed on VSMC’s does not bind IL-2 in a carbohydrate-dependent manner.
Since IL-2’s main function is regulating T cell proliferation, we asked if treatment
of VSMC’s with IL-2 induces a proliferative response. Interestingly, IL-2 increases
VSMC proliferation, suggesting that in vivo exposure of VSMC’s to IL-2 may
affect the development of new blood vessels and/or the regeneration of
vasculature following injury.
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IL-2 is used as an immunotherapy due to its ability to increase T-cell
proliferation and differentiation. Although this treatment can cause regression of
tumor metastases, it is associated with multiple side effects including vascular
leak syndrome, left ventricular dysfunction, increased cardiac output, and
decreased systemic vascular resistance [48]. The most significant dose-limiting
side effect is vascular leak syndrome, which entails increased vascular
permeability causing a leakage of fluid from the circulatory system into the
interstitial space resulting in ascites, hydrothorax, pulmonary edema, and
hypotension.
Previous studies have shown that IL-2 increases the expression of
adhesion molecules such as ICAM-1 in endothelial cells and beta-2 integrin in
neutrophils. Increased expression of these adhesion molecules has been
proposed to be part of the mechanism underlying vascular leak syndrome [49,
50]. Whether IL-2 binding to its receptor in SMCs increases expression of these
adhesion molecules is under investigation. However, given the responsivity of
VSMC’s to IL-2 described in the current work, it seems likely that some aspect of
vascular leak syndrome could be caused by a direct effect of high dose IL-2 on
VSMC’s.
Abnormal VSMC proliferation is thought to play a critical role in
atherosclerosis and restenosis. In response to injury of the blood vessel
endothelial cell layer, cholesterol, and cellular waste products accumulate in the
damaged area, inducing endothelial cells to produce pro-inflammatory cytokines.
As a response to this inflammation, leukocytes adhere to the endothelial layer
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[51]. This may cause the production of cytokines including IL-2. Based on our
finding that IL-2 increases SMC proliferation in vitro, exposure of VSMC’s to IL-2
during an inflammatory event would cause them to proliferate, causing
fibromuscular lesions, which are characterized as abnormal growth within the
vessel wall. As a result of this process, the artery wall thickens, leading to
reduced blood flow, which may contribute to atherosclerosis or restenosis. Our
lab has previously described the binding of IL-2 to heparan sulfate (HS)
carbohydrates within the blood vessel wall [3]. Cleavage of the HS carbohydrates
by heparanase was shown to release biologically active IL-2. Liberation of HSbound IL-2 by heparanase released by T-cells during extravasation through the
vessel wall could, in turn, induce the proliferation of VSMCs [3].
Previous work has demonstrated that SMC’s produce multiple
immunoregulatory factors including IL-6, IL-8, and TNF- α [52, 53, 54, 55]. Given
these previous studies, future work assessing the ability of VSMC’s to produce
IL-2, which could work in an autocrine fashion as it does with T cells is
reasonable. The current work demonstrates the involvement of the Beta subunit
of the IL-2R in binding IL-2. Expanding these studies to assess involvement of
the alpha and possibly the gamma subunits would better define the interaction of
IL-2 with the IL-2R expressed on VSMC’s. One approach would be to assess
how small interfering RNA (siRNA) specific for the alpha, beta, or gamma
subunits affect the ability of SMC’s to proliferate in response to exposure to IL-2
in vitro. In addition, determining if IL-2 induces the proliferation of vessel
endothelial cells would provide a broader vision of the influence of IL-2 on non-
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lymphoid cells of the vasculature. The aortas of IL-2 deficient mice are
characterized by an abnormal cytoarchitecture of the SMC layer [3] suggesting
that IL-2 may have an effect on the development or maintenance of a normal
vessel wall. In addition, smooth muscle cell α-actin (SMC α-actin) is a protein
known to play a critical role in the differentiation of VSMC. Determining if
administration of IL-2 to IL-2 knock-out mice results in a more normal VSMC
layer and the expression of SMC α-actin would allow an assessment of the role
played by IL-2 during blood vessel development. Understanding the mechanisms
that regulate expression of the IL-2R by VSMCs and how binding of this receptor
by IL-2 effects VSMC biology will provide a better understanding of the
mechanisms underlying vascular development and diseases of the vasculature
such as atherosclerosis, and restenosis.
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Figure 1. Human Vascular Smooth Muscle Cells Express the Alpha (α), Beta
(β) but not the Gamma (γ) subunit of IL-2R. Using in-cell Western analysis,
cultured VSMCs were probed with antibodies directed against α, β, and γ
subunits of the IL-2R. Isotype indicates biotinylated mouse IgG, and control
indicates cells alone with no antibodies. Error bars represent the means ± SD of

triplicate wells, and representative of 3 separate experiments. Analysis of variance
(ANOVA): P < 0.05

20

Fluorescence
(Ex. 660 nm, Em. 694nm)

4000

3000

2000

**
1000

0

IL-2

IL-2 + anti IL-2R β

Cells only

Figure 2. VSMCs bind dye-labeled glycosylated IL-2 via IL-2R β.
Cultured VSMCs were probed with dye labeled glycosylated IL-2 after preincubation with or without anti- IL-2R β antibodies. Error bars represent the
means ± SD of triplicate wells, and representative of 3 separate experiments.
Analysis of t test: **(P < 0.05).
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Figure 3. VSMCs bind dye-labeled non-glycosylated IL-2 via IL-2R β.
Cultured VSMCs were probed with dye labeled non-glycosylated IL-2 after preincubation with or without anti- IL-2R β antibodies. Error bars represent the
means ± SD of triplicate wells, and representative of 3 separate experiments.
Analysis of t test: *(P < 0.05).
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Figure 4. Exposure of VSMCs to lipopolysaccharide decreases IL-2Rβ
expression. Using in-cell Western analysis, cultured vascular smooth muscle
cells were probed with an antibody directed against the β subunit of the IL-2R
after 48 hours incubation with lipopolysaccharide (LPS; 1 ug/ml). Isotype
indicates biotinylated mouse IgG, and control indicates cells alone with no
antibodies. Error bars represent the means ± SD of triplicate wells, and

representative of 3 separate experiments. Analysis of t test: **(P < 0.05)
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Figure 5. Treatment of Vascular Smooth Muscle Cells with IL-2 increases
expression of the IL-2R gamma subunit . Using in-cell Western analysis,
cultures were probed with an antibody directed against the gamma subunit of the
IL-2R following 24 hours incubation with IL-2 (4 ng/ml). Isotype indicates
biotinylated mouse IgG, and control indicates cells alone with no antibodies.
Error bars represent the means ± SD of triplicate wells, and representative of 3

separate experiments. Analysis of t test: **(P < 0.05)
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Figure 6: Exposure of Vascular Smooth Muscle Cells to IL-2 increases SMC
Proliferation.
VSMCs incubated for 48 hours with 25ng/ml IL-2 or media alone. Proliferation of
VSMCs was assessed by MTS-based assay” CellTiter 96 One Aqueous Solution
Cell Proliferation Assay”. Error bars represent the means ± SD of triplicate wells,

and representative of 4 separate experiments. Analysis of t test: ****(P < 0.05)
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Appendix A
In-Cell Western Protocol

Materials required:

Fixative: Ice-cold Methanol with 2% v/v Acetic Acid.

Assay Buffer: Tris-baffered Saline + 0.1% Tween (TTBS)
1) Gently wash plate 1X with PBS (100 L/well)
2) Fix for 5 minutes in ice-cold Methanol with 2% v/v Acetic Acid (100 L/well).
After fixation, put the plate in the fridge for 5 mins.
3) Gently wash 3X with PBS (100 L/well).

4) Block for 2 hours at room temperature with Odyssey block solution with 1% v/v
Mouse serum (150 L/well).

5) Wash 3X with TTBS (100uL/well).

6) Incubate wells with primary antibodies suspended in TTBS overnight at room
temperature.

Antibody

Concentration/ml

Anti-alpha

10g/ml

Anti-Beta

10g/ml

Anti-Gamma

10g/ml
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Next Day
7) Wash wells 3X with TTBS (100 L/well).

8) To detect biotinylated antibodies, probe wells with Avidinylated secondary
used at 10g/ml. Incubate for 1.5 hours at room temperature.

9) Wash the plate 3X with TTBS.

10) Read the plate immediately.

11) Place in dry dark place (closed drawer) and allow to dry overnight for 16
hours.

11) Re-read dry plate the next morning.
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Appendix B
IL-2 Binding Studies

Materials Required:

Fixative: Ice-cold Methanol with 2% v/v Acetic Acid.

Assay Buffer: PBS only

Protocol:
1) Wash wells 2X with PBS.

3) Pre-incubate 500ng/ml fluor IL-2 for 20 minutes at 4C.

4) Wash wells 3X with PBS.
5) Place 100 L of Fix solution in each well and incubate at 4C for 15 minutes.

6) Wash wells 2X with PBS.

7) Read on Synergy (wet).

8) Allow wells to air dry in the dark and re-read (dry).
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Appendix C
SMC Proliferation Studies

1- Maintain a plate of SMCs in SMC medium supplemented with 25ng/ml human
recombinant IL-2 for 48 hours.

2- Thaw the CellTiter 96® AQueous One Solution Reagent. It should take
approximately 90 minutes at room temperature, or 10 minutes in a water bath at
37°C, for completely thawing.
3- Pipet 20μl of CellTiter 96® AQueous One Solution Reagent into each well of
the 96-well assay plate containing the SMC cells in 100μl of SMC medium.
4- Incubate the plate at 37°C for 1–4 hours in a humidified, 5% CO2 atmosphere.
5- Record the absorbance at 490nm using a 96-well Synergy plate reader.
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